Martin J. Walshaw
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Martin J. Walshaw has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Matthew Shaw
Institute of Cardiovascular Medicine and Science, Department of Cardiology, Liverpool Heart and Chest Hospital, Thomas Drive, Liverpool, L14 3PE, UK
4 shared publications Abdul Ashish
Liverpool Heart and Chest Hospital , Liverpool L14 3PE , UK
3 shared publications- Craig Winstanley
Institute of Infection and Global Health, University of Liverpool, Liverpool, UK
2 shared publications - Dilip Nazareth
Adult CF Unit, Liverpool Heart and Chest Hospital NHS Foundation Trust, Liverpool, England, UK
2 shared publications - Anke Seegebarth
Bavarian Nordic GmbH, Berlin, Germany
1 shared publication - Bernd Schmidt
11Universitätsklinik und Poliklinik für Innere Medizin I, Universitätsklinikum Halle (Saale), Halle, Germany
1 shared publication
Latest Publications
- Open Access
- 20 October 2020
- Published by Springer Nature in Cureus
- Vol. 12 (10)
Mycobacterium Simiae Infection in a Person With Cystic Fibrosis
Although non-tuberculous mycobacteria can be found in the airways of people with cystic fibrosis (pwCF), their role as pathogens may be uncertain, and treatment is problematic. We report the first case of Mycobacterium simiae (M. simiae), often associated with asymptomatic disease or colonisation, which caused pulmonary infection requiring treatment in a pwCF. This report shows that M. simiae, rare in pwCF in the United Kingdom, can cause significant illness and highlights the diagnostic difficulty in individuals with positive smear mycobacteria that can be mistaken initially for pulmonary tuberculosis (TB).
- 20 October 2020
- Published by Springer Nature in Cureus
- Vol. 12 (10)
Open AccessMycobacterium Simiae Infection in a Person With Cystic Fibrosis
Although non-tuberculous mycobacteria can be found in the airways of people with cystic fibrosis (pwCF), their role as pathogens may be uncertain, and treatment is problematic. We report the first case of Mycobacterium simiae (M. simiae), often associated with asymptomatic disease or colonisation, which caused pulmonary infection requiring treatment in a pwCF. This report shows that M. simiae, rare in pwCF in the United Kingdom, can cause significant illness and highlights the diagnostic difficulty in individuals with positive smear mycobacteria that can be mistaken initially for pulmonary tuberculosis (TB).
- 1 August 2019
- Published by Elsevier in Paediatric Respiratory Reviews
- Vol. 31, 12-14
Cystic fibrosis: Diagnosis and management – NICE guideline 78
- 1 August 2019
- Published by Elsevier in Paediatric Respiratory Reviews
- Vol. 31, 12-14
Cystic fibrosis: Diagnosis and management – NICE guideline 78
- 1 March 2019
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 18 (2) , 294-298
Cystic fibrosis related diabetes is not independently associated with increased Stenotrophomonas maltophilia infection: Longitudinal data from the UK CF Registry
- 1 March 2019
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 18 (2) , 294-298
Cystic fibrosis related diabetes is not independently associated with increased Stenotrophomonas maltophilia infection: Longitudinal data from the UK CF Registry
- Open Access
- 1 January 2013
- Published by SAGE Publications in JRSM Short Reports
- Vol. 4 (1) , 1-8
Halting the spread of epidemic Pseudomonas aeruginosa in an adult cystic fibrosis centre: a prospective cohort study
Summary Objectives: To assess if cohort segregation policies are effective in preventing cross-infection in cystic fibrosis (CF) clinics. Design: A prospective cohort study. Setting: A large adult CF centre in Northwest England. Participants: All CF patients cared for at the Liverpool adult CF centre 2003–2009. Methods: Regular sputum sampling with genotyping of Pseudomonas aeruginosa (Psa) isolates led to a policy of inpatient and outpatient segregation by microbiological group. Main outcome measures: Prevalence and cross-infection/super-infection rates of a transmissible Psa strain, i.e. the Liverpool epidemic strain (LES) in adult CF patients at the Liverpool adult CF centre from 2003 to 2009. Results: There was a decline in the proportion of patients with LES (71–53%) and an increase in those with unique strains (23–31%) and without Psa infection (6–17%) from 2003 to 2009. There were two cases of LES super-infection and one case of new chronic Psa infection (with a unique strain). There were no cases of transmissible strain infection in patients previously uninfected by Psa. Conclusions: Our segregation policy has halted the spread of the commonest highly transmissible strain in the UK (LES) in our clinic, without endangering patients who were not previously infected with Psa. It confirms that if genotypic surveillance is used, it is unnecessary to segregate patients infected with unique strains from those without Psa infection.
- 1 January 2013
- Published by SAGE Publications in JRSM Short Reports
- Vol. 4 (1) , 1-8
Open AccessHalting the spread of epidemic Pseudomonas aeruginosa in an adult cystic fibrosis centre: a prospective cohort study
Summary Objectives: To assess if cohort segregation policies are effective in preventing cross-infection in cystic fibrosis (CF) clinics. Design: A prospective cohort study. Setting: A large adult CF centre in Northwest England. Participants: All CF patients cared for at the Liverpool adult CF centre 2003–2009. Methods: Regular sputum sampling with genotyping of Pseudomonas aeruginosa (Psa) isolates led to a policy of inpatient and outpatient segregation by microbiological group. Main outcome measures: Prevalence and cross-infection/super-infection rates of a transmissible Psa strain, i.e. the Liverpool epidemic strain (LES) in adult CF patients at the Liverpool adult CF centre from 2003 to 2009. Results: There was a decline in the proportion of patients with LES (71–53%) and an increase in those with unique strains (23–31%) and without Psa infection (6–17%) from 2003 to 2009. There were two cases of LES super-infection and one case of new chronic Psa infection (with a unique strain). There were no cases of transmissible strain infection in patients previously uninfected by Psa. Conclusions: Our segregation policy has halted the spread of the commonest highly transmissible strain in the UK (LES) in our clinic, without endangering patients who were not previously infected with Psa. It confirms that if genotypic surveillance is used, it is unnecessary to segregate patients infected with unique strains from those without Psa infection.
- Open Access
- 27 February 2012
- Published by SAGE Publications in JRSM Short Reports
- Vol. 3 (2) , 1-7
Health-related quality of life in Cystic Fibrosis patients infected with transmissible Pseudomonas aeruginosa strains: cohort study
Objectives: To assess the impact on health-related quality of life (HRQoL) in adult cystic fibrosis (CF) patients of chronic infection with the Liverpool Epidemic Strain (LES) of Pseudomonas aeruginosa (Psa). Design: Cohort study. Participants: Adult CF patients attending a single CF centre. Setting: Outpatient clinic. Main outcome measures: HRQoL measures of adult CF patients chronically infected with LES and Psa strains measured by CFQ-UK. Results: Patients infected by transmissible Psa strains had worse physical functioning, respiratory symptoms, treatment burden, vitality, role, health perception and emotion than those with unique Psa strains ( P < 0.01), and significantly poorer physical functioning, respiratory symptoms, treatment burden, body image, weight, role, and emotion than those without any Psa infection ( P < 0.05). Furthermore, in a matched cohort of 39 patients, those with LES infection reported significantly worse physical functioning, treatment burden, respiratory symptoms and health perception than those with unique Psa infection (P < 0.02). Conclusion: Chronic infection with transmissible Psa strains, particularly LES, confers a worse quality of life in adult CF patients. Coupled with the established poorer clinical outcome, this reinforces the need to prevent the spread of such strains in CF community.
- 27 February 2012
- Published by SAGE Publications in JRSM Short Reports
- Vol. 3 (2) , 1-7
Open AccessHealth-related quality of life in Cystic Fibrosis patients infected with transmissible Pseudomonas aeruginosa strains: cohort study
Objectives: To assess the impact on health-related quality of life (HRQoL) in adult cystic fibrosis (CF) patients of chronic infection with the Liverpool Epidemic Strain (LES) of Pseudomonas aeruginosa (Psa). Design: Cohort study. Participants: Adult CF patients attending a single CF centre. Setting: Outpatient clinic. Main outcome measures: HRQoL measures of adult CF patients chronically infected with LES and Psa strains measured by CFQ-UK. Results: Patients infected by transmissible Psa strains had worse physical functioning, respiratory symptoms, treatment burden, vitality, role, health perception and emotion than those with unique Psa strains ( P < 0.01), and significantly poorer physical functioning, respiratory symptoms, treatment burden, body image, weight, role, and emotion than those without any Psa infection ( P < 0.05). Furthermore, in a matched cohort of 39 patients, those with LES infection reported significantly worse physical functioning, treatment burden, respiratory symptoms and health perception than those with unique Psa infection (P < 0.02). Conclusion: Chronic infection with transmissible Psa strains, particularly LES, confers a worse quality of life in adult CF patients. Coupled with the established poorer clinical outcome, this reinforces the need to prevent the spread of such strains in CF community.
- 7 December 2011
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 11 (3) , 173-179
Increasing resistance of the Liverpool Epidemic Strain (LES) of Pseudomonas aeruginosa (Psa) to antibiotics in cystic fibrosis (CF)—A cause for concern?
- 7 December 2011
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 11 (3) , 173-179
Increasing resistance of the Liverpool Epidemic Strain (LES) of Pseudomonas aeruginosa (Psa) to antibiotics in cystic fibrosis (CF)—A cause for concern?
- Open Access
- 3 November 2010
- Published by Springer Nature in BMC Cancer
- Vol. 10 (1) , 600
SHOX2 DNA Methylation is a Biomarker for the diagnosis of lung cancer based on bronchial aspirates
Background: This study aimed to show that SHOX2 DNA methylation is a tumor marker in patients with suspected lung cancer by using bronchial fluid aspirated during bronchoscopy. Such a biomarker would be clinically valuable, especially when, following the first bronchoscopy, a final diagnosis cannot be established by histology or cytology. A test with a low false positive rate can reduce the need for further invasive and costly procedures and ensure early treatment. Methods: Marker discovery was carried out by differential methylation hybridization (DMH) and real-time PCR. The real-time PCR based HeavyMethyl technology was used for quantitative analysis of DNA methylation of SHOX2 using bronchial aspirates from two clinical centres in a case-control study. Fresh-frozen and Saccomanno-fixed samples were used to show the tumor marker performance in different sample types of clinical relevance. Results: Valid measurements were obtained from a total of 523 patient samples (242 controls, 281 cases). DNA methylation of SHOX2 allowed to distinguish between malignant and benign lung disease, i.e. abscesses, infections, obstructive lung diseases, sarcoidosis, scleroderma, stenoses, at high specificity (68% sensitivity [95% CI 62-73%], 95% specificity [95% CI 91-97%]). Conclusions: Hypermethylation of SHOX2 in bronchial aspirates appears to be a clinically useful tumor marker for identifying subjects with lung carcinoma, especially if histological and cytological findings after bronchoscopy are ambiguous.
- 3 November 2010
- Published by Springer Nature in BMC Cancer
- Vol. 10 (1) , 600
Open AccessSHOX2 DNA Methylation is a Biomarker for the diagnosis of lung cancer based on bronchial aspirates
Background: This study aimed to show that SHOX2 DNA methylation is a tumor marker in patients with suspected lung cancer by using bronchial fluid aspirated during bronchoscopy. Such a biomarker would be clinically valuable, especially when, following the first bronchoscopy, a final diagnosis cannot be established by histology or cytology. A test with a low false positive rate can reduce the need for further invasive and costly procedures and ensure early treatment. Methods: Marker discovery was carried out by differential methylation hybridization (DMH) and real-time PCR. The real-time PCR based HeavyMethyl technology was used for quantitative analysis of DNA methylation of SHOX2 using bronchial aspirates from two clinical centres in a case-control study. Fresh-frozen and Saccomanno-fixed samples were used to show the tumor marker performance in different sample types of clinical relevance. Results: Valid measurements were obtained from a total of 523 patient samples (242 controls, 281 cases). DNA methylation of SHOX2 allowed to distinguish between malignant and benign lung disease, i.e. abscesses, infections, obstructive lung diseases, sarcoidosis, scleroderma, stenoses, at high specificity (68% sensitivity [95% CI 62-73%], 95% specificity [95% CI 91-97%]). Conclusions: Hypermethylation of SHOX2 in bronchial aspirates appears to be a clinically useful tumor marker for identifying subjects with lung carcinoma, especially if histological and cytological findings after bronchoscopy are ambiguous.
- 15 July 2009
- Published by SAGE Publications in Journal of the Royal Society of Medicine
- Vol. 102 (1_suppl) , 40-44
Routine OGTT screening for CFRD - no thanks
Subscription and open access journals from SAGE Publishing, the world's leading independent academic publisher.
- 15 July 2009
- Published by SAGE Publications in Journal of the Royal Society of Medicine
- Vol. 102 (1_suppl) , 40-44
Routine OGTT screening for CFRD - no thanks
Subscription and open access journals from SAGE Publishing, the world's leading independent academic publisher.